COMPANY PROFILE

GT Medical Technologies

Explore full profile

GT Medical Technologies has developed a unique therapeutic approach to the treatment of brain tumors

Mesa, United StatesFounded 2017Biotech & Life Sciences

Valuation $100–500M Latest valuation · 2026

Headcount 100–500 Current team size

Total funding $100–500M Disclosed equity funding

Unlock exact values

About GT Medical Technologies

GT Medical Technologies is a healthcare startup that specializes in the development and commercialization of innovative treatments for patients with brain tumors. The company's flagship product, GammaTile®, is a surgically targeted radiation therapy designed to treat patients with newly diagnosed malignant intracranial neoplasms (brain tumors) and those with recurrent intracranial neoplasms.

Read full description

The company operates in the healthcare and medical technology market, specifically in the field of oncology. Its primary clients are healthcare providers and institutions that treat patients with brain tumors. GT Medical Technologies' business model revolves around the development, regulatory approval, and commercialization of its GammaTile® therapy. The company generates revenue by selling its product to healthcare providers and institutions.

GammaTile® is a unique product that combines surgical precision with radiation therapy. It is implanted in the brain during surgery and delivers a dose of radiation directly to the tumor site, reducing the risk of damage to healthy brain tissue. This innovative approach has been proven safe and effective in clinical trials, making it a promising treatment option for patients with brain tumors.

In summary, GT Medical Technologies is a promising startup in the medical technology sector, offering a unique and effective treatment for brain tumors. Its innovative product, GammaTile®, has the potential to significantly improve the quality of life for patients and create a new standard of care in the treatment of brain tumors.

Source: Dealroom company data

At a glance

Status: Operational
Founded: 2017
Headquarters: Mesa, United States
Employees: 110
Open positions: 2
Dealroom signal: 83.3/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Oncology, Neurology, Biotech and Pharma, Woman Founder, DT and LS, science-based
Technology: Deep Tech
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn X

Latest news

Press, funding announcements and product moves mentioning GT Medical Technologies.

See all news

Funding history

9 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES EOther financing	Jun 2026	$100M	$400M	MVM Life Science Partners · Evidity Health Capital · Viking Global Investors · Gilde Healthcare	↗
SERIES DOther financing	Jul 2025	$16M	$225M	Warren Point Capital · FemHealth Ventures	↗

Showing the latest 2 of 9 recorded eventsBook a demo for the full funding history →

Growth signals

GT Medical Technologies website traffic

Latest recorded traffic for GT Medical Technologies is 5K monthly website visits, up 6.4% over the last three months. GT Medical Technologies's team grew 10% over the past year.

Latest monthly visits5K 3-month web change+6.4% 1-year team growth+10%

Monthly website visitsOct 2017–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
ATAmbagon TherapeuticsBiotechnology company developing small molecule drugs that target previously undruggable proteins for cancer treatment	Eindhoven, Netherlands	Operational	15	$97M	$425M
RIRigontecRNA-based immunotherapeutics for the treatment of cancer and viral diseases	Bonn, Germany	Acquired
VEVectiopepDevelop cancer immunotherapy	Tartu, Estonia	Operational
YTYsotope TheranosticsTargeted radiopharmaceuticals for precision oncology	Madrid, Spain	Operational
SNSwan NeuroTechDeveloping biodegradable implants that deliver drugs to promote nerve regeneration after injury.	Pittsburgh, United States	Operational
BIBioSapienBiosapien develops 3D-printed, biocompatible drug delivery implants for localized cancer treatment, reducing chemotherapy side effects and expanding global access to advanced oncology care	San Diego, United States	Operational
OMOnena MedicinesRevolutionary AI-optimized medicines delivering hope where it’s needed most	Allschwil, Switzerland	Operational
GAGate2brainBiotech company improving drug delivery to the brain using a peptide-based patented technology	Barcelona, Spain	Operational